stoxline Quote Chart Rank Option Currency Glossary
  
Verona Pharma plc (VRNA)
75.06  2.37 (3.26%)    05-23 16:00
Open: 71.52
High: 75.4
Volume: 815,089
  
Pre. Close: 72.69
Low: 71
Market Cap: 6,379(M)
Technical analysis
2025-05-23 4:52:04 PM
Short term     
Mid term     
Targets 6-month :  88.3 1-year :  103.13
Resists First :  75.59 Second :  88.3
Pivot price 70.22
Supports First :  65.26 Second :  58.88
MAs MA(5) :  73.83 MA(20) :  70.62
MA(100) :  61.66 MA(250) :  41.65
MACD MACD :  2.5 Signal :  2.2
%K %D K(14,3) :  89 D(3) :  89.5
RSI RSI(14): 64.3
52-week High :  75.59 Low :  11.39
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ VRNA ] has closed below upper band by 13.4%. Bollinger Bands are 8.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 75.44 - 75.81 75.81 - 76.19
Low: 70.16 - 70.53 70.53 - 70.91
Close: 74.44 - 75.05 75.05 - 75.67
Company Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Headline News

Wed, 21 May 2025
Verona Pharma Announces June 2025 Investor Conference Participation | VRNA Stock News - GuruFocus

Wed, 21 May 2025
Verona Pharma Secures Speaking Slots at Two Major Healthcare Investor Conferences This June - Stock Titan

Wed, 21 May 2025
Verona Pharma Announces June 2025 Investor Conference Participation - GlobeNewswire

Tue, 13 May 2025
Why Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy Now - Yahoo Finance

Tue, 06 May 2025
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 - GlobeNewswire

Thu, 01 May 2025
This Just In: Analysts Are Boosting Their Verona Pharma plc (NASDAQ:VRNA) Outlook for This Year - simplywall.st

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 85 (M)
Shares Float 526 (M)
Held by Insiders 34.6 (%)
Held by Institutions 86.8 (%)
Shares Short 8,000 (K)
Shares Short P.Month 9,130 (K)
Stock Financials
EPS -2
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.49
Profit Margin -138.4 %
Operating Margin -13.6 %
Return on Assets (ttm) -20.7 %
Return on Equity (ttm) -72.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 1.32
Sales Per Share 1.39
EBITDA (p.s.) -1.57
Qtrly Earnings Growth 0 %
Operating Cash Flow -120 (M)
Levered Free Cash Flow -69 (M)
Stock Valuations
PE Ratio -37.53
PEG Ratio 0
Price to Book value 30.14
Price to Sales 53.9
Price to Cash Flow -53.19
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android